NRXP
Income statement / Annual
Last year (2025), NRX Pharmaceuticals Inc's total revenue was $1.23 M,
and the percentage change from the previous year is not available.
In 2025, NRX Pharmaceuticals Inc's net income was -$28.62 M.
See NRX Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$1.23 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$505.00 K
|
$5.00 K
|
$5.00 K
|
$4.00 K
|
$2.00 K
|
$2.00 K
|
$0.00
|
$1.01 M
|
$0.00
|
| Gross Profit |
$720.00 K
|
-$5.00 K
|
-$5.00 K
|
-$4.00 K
|
-$2.00 K
|
-$2.00 K
|
$0.00
|
-$1.01 M
|
$0.00
|
| Gross Profit Ratio |
0.59
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$3.78 M
|
$6.20 M
|
$13.37 M
|
$17.03 M
|
$20.26 M
|
$10.63 M
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$13.06 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$13.06 M
|
$13.50 M
|
$14.21 M
|
$27.30 M
|
$74.94 M
|
$11.43 M
|
$713.19 K
|
$1.01 M
|
$0.00
|
| Other Expenses |
$106.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$16.94 M
|
$19.70 M
|
$27.58 M
|
$44.33 M
|
$95.20 M
|
$22.06 M
|
$713.19 K
|
$0.00
|
$0.00
|
| Cost And Expenses |
$17.45 M
|
$19.70 M
|
$27.59 M
|
$44.34 M
|
$95.20 M
|
$22.06 M
|
$713.19 K
|
$1.01 M
|
$0.00
|
| Interest Income |
$12.00 K
|
$44.00 K
|
$494.00 K
|
$249.00 K
|
$18.00
|
$56.00
|
$1.21 M
|
$1.09 M
|
$0.00
|
| Interest Expense |
$671.00 K
|
$1.08 M
|
$120.00 K
|
$0.00
|
$18.00 K
|
$56.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$143.00 K
|
$5.00 K
|
$5.00 K
|
$4.00 K
|
$2.00 K
|
$2.00 K
|
$0.00
|
$0.00
|
$52.52 K
|
| EBITDA |
-$27.81 M |
-$24.04 M |
-$30.03 M |
-$39.75 M |
-$93.04 M |
-$51.72 M |
$492.63 K |
$82.41 K |
-$105.00 K |
| EBITDA Ratio |
-22.7
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-13.24
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$12.40 M
|
-$5.42 M
|
-$2.56 M
|
$4.58 M
|
$2.14 M
|
-$29.72 M
|
$1.21 M
|
$1.09 M
|
-$105.00 K
|
| Income Before Tax |
-$28.62 M
|
-$25.13 M
|
-$30.15 M
|
-$39.75 M
|
-$93.06 M
|
-$51.78 M
|
$492.63 K
|
$82.41 K
|
-$105.00 K
|
| Income Before Tax Ratio |
-23.36
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$84.21 K
|
$16.31 K
|
$0.00
|
| Net Income |
-$28.62 M
|
-$25.13 M
|
-$30.15 M
|
-$39.75 M
|
-$93.06 M
|
-$51.78 M
|
$408.43 K
|
$66.10 K
|
-$105.00 K
|
| Net Income Ratio |
-23.36
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.34 |
-2.39 |
-3.98 |
-0.6 |
-7.44 |
-1.51 |
0.8 |
0.0741 |
-0.12 |
| EPS Diluted |
-1.34 |
-2.39 |
-3.98 |
-0.6 |
-7.44 |
-1.51 |
0.8 |
0.0741 |
-0.12 |
| Weighted Average Shares Out |
$21.40 M
|
$10.52 M
|
$7.58 M
|
$65.77 M
|
$46.92 M
|
$546.59 K
|
$508.84 K
|
$892.50 K
|
$903.55 K
|
| Weighted Average Shares Out Diluted |
$21.40 M
|
$10.52 M
|
$7.58 M
|
$65.77 M
|
$46.92 M
|
$546.59 K
|
$508.84 K
|
$892.50 K
|
$903.55 K
|
| Link |
|
|
|
|
|
|
|
|
|
